Detalles de la búsqueda
1.
Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis.
Hepatology
; 68(6): 2145-2157, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30070722
2.
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study.
N Engl J Med
; 373(21): 2048-58, 2015 Nov 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-26580997
3.
ALS-008176 for Respiratory Syncytial Virus Infection.
N Engl J Med
; 374(14): 1391-2, 2016 04 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27050226
4.
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI).
Am Heart J
; 160(1): 65-72, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20598974
5.
Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir.
AAPS J
; 21(1): 1, 2018 10 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-30377854
6.
Characterizing the Pharmacokinetic Interaction Between Simeprevir and Odalasvir in Healthy Volunteers Using a Population Modeling Approach.
AAPS J
; 20(6): 111, 2018 10 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-30350297
7.
Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects.
PLoS One
; 13(10): e0204974, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30325939
8.
Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjects.
Pharmacol Res Perspect
; 6(3): e00395, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29736243
9.
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.
Circ Cardiovasc Interv
; 5(3): 336-46, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22647518
10.
Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial.
Circ Cardiovasc Interv
; 5(3): 347-56, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22619259
Resultados
1 -
10
de 10
1
Próxima >
>>